Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Neurovascular bundle sparing boosts postoperative sexual function in prostate cancer patients
The width of the spared neurovascular bundle (NVB) is an important indicator of postoperative sexual function after robot-assisted laparoscopic prostatectomy for prostate cancer, a recent study has found. These findings point to NVB as an easy intraoperative marker for assessing postoperative outcomes.
Neurovascular bundle sparing boosts postoperative sexual function in prostate cancer patients
08 Oct 2021ADT-docetaxel-abiraterone: A winning combo for mCSPC
Triplet therapy combining androgen deprivation therapy (ADT), docetaxel, and abiraterone-prednisone improves overall survival (OS) in men with de novo metastatic castration-sensitive prostate cancer (mCSPC), according to results of the phase III PEACE-1 trial presented at ESMO 2021.
ADT-docetaxel-abiraterone: A winning combo for mCSPC
07 Oct 2021Acid suppression drugs counteract EGFR-TKIs for NSCLC treatment
Acid suppression (AS) medications, such as proton pump inhibitors (PPIs) and histamine type-2 receptor antagonists (H2RAs), weaken the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in nonsmall cell lung cancer (NSCLC), resulting in worse survival outcomes, according to a recent Singapore meta-analysis.
Acid suppression drugs counteract EGFR-TKIs for NSCLC treatment
07 Oct 2021CV safety of degarelix vs leuprolide: Results remain inconclusive
In men with prostate cancer and concomitant atherosclerotic cardiovascular disease (ASCVD), major adverse cardiovascular event (MACE) incidence did not differ between those who were treated with degarelix or leuprolide, according to findings of the PRONOUNCE trial.
CV safety of degarelix vs leuprolide: Results remain inconclusive
06 Oct 2021Extended letrozole therapy improves DFS in postmenopausal women with breast cancer
Extending treatment with letrozole for 5 years improves disease-free survival (DFS) rates in postmenopausal women with early-stage breast cancer who have already received tamoxifen for 2–3 years, according to the GIM4* trial.